Latest news with #AdamFeinberg
Business Upturn
24-04-2025
- Health
- Business Upturn
FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) — FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development of CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), a fully-biologic, 3D-bioprinted tissue platform engineered for internal perfusion and organ-level function. The work, led by Dr. Adam Feinberg and colleagues at Carnegie Mellon University, demonstrates the ability to fabricate centimeter-scale tissue constructs combining cells and extracellular matrix with unprecedented precision and functional fidelity. This new CHIPS platform provides a crucial technological bridge between foundational FRESH™ 3D bioprinting capabilities and FluidForm Bio's therapeutic mission—to create vascularized tissue constructs that support the viability and function of implanted islet cells. 'CHIPS represent the next generation of tissue scaffolding,' said Andrew Hudson, PhD, Co-Founder of FluidForm Bio and co-author of the paper. 'They enable not just structure, but function—supporting dynamic perfusion, vascularization, and even glucose-stimulated insulin secretion in engineered tissue constructs. This is the kind of platform our therapeutic programs require.' By combining native extracellular matrix components such as collagen and fibrin with vascular and endocrine cells—including insulin-secreting MIN6 beta-like cells—the study achieves a first: a fully-biologic, perfusable pancreatic-like tissue that responds to glucose and secretes insulin. Under perfusion, these constructs exhibited significant cell migration, vascular network formation, and insulin output, with a stimulation index beyond what is achieved with traditional biofabrication approaches. 'These results validate FRESH as the enabling technology not only for research but for our ongoing clinical translation,' said Adam Feinberg, PhD, who is also Co-Founder and Chief Technology Officer of FluidForm Bio. 'The constructs described in this paper are essentially blueprints for what we're building at FluidForm—fully cellularized, vascularized tissues for subcutaneous implantation and therapeutic function.' The CHIPS paper adds momentum to FluidForm Bio's islet cell replacement therapy program, which leverages FRESH printing to create implantable tissue scaffolds that maintain islet health, support vascularization, and promote long-term glycemic control without the need for systemic immunosuppression. The company has demonstrated sustained normoglycemia in preclinical models for over five months using this approach. The publication coincides with FluidForm Bio's live equity crowdfunding campaign on StartEngine, which invites supporters to participate in advancing the future of regenerative medicine. The paper can be found online here: About FluidForm Bio™ FluidForm Bio™ is a biotechnology company developing next-generation cell therapies for chronic diseases leveraging its proprietary FRESH™ 3D bioprinting technology platform. Using FRESH, FluidForm creates functional tissue with the same materials found in the human body, eliminating chemistries and materials known to trigger negative immune response. FRESH is a powerful vascularization platform, allowing the building of densely cellular vascularized tissue that maintains viability upon implant. The company's lead program is an islet cell therapy for type 1 diabetes in which insulin-producing beta cells are arranged in a tissue scaffold ready for subcutaneous implantation. This method is less invasive and less toxic when compared to other delivery sites, offering retrievability and reducing surgical risks and recovery time for patients. This novel approach to islet cell replacement therapy presents a transformative advancement in diabetes treatment. With superior fabrication techniques, enhanced vascularization, a robust immune modulation platform, and a convenient subcutaneous implant, this method addresses many limitations of current technologies. These improvements offer the potential for a more effective, durable, and patient-friendly therapy, offering new hope for individuals with diabetes. Founded in 2018, FluidForm is headquartered in Waltham, MA. To learn more, please visit: or connect on Twitter and LinkedIn. Contact:Corey Davis, Advisors+1 212 915 2577 [email protected]
Business Wire
23-04-2025
- Health
- Business Wire
Carnegie Mellon University's Feinberg Lab's FRESH bioprinting technique brings vascularized tissue one step closer
PITTSBURGH--(BUSINESS WIRE)--Collagen is well-known as an important component of skin, but its impact is much greater, as it is the most abundant protein in the body, providing structure and support to nearly all tissues and organs. Using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique, which allows for the printing of soft living cells and tissues, Carnegie Mellon's Feinberg lab has built a first-of-its-kind microphysiologic system, or tissue model, entirely out of collagen. This advancement expands the capabilities of how researchers can study disease and build tissues for therapy, such as Type 1 diabetes. Using their novel (FRESH 3D bioprinting technique, which allows for the printing of soft living cells and tissues, Carnegie Mellon's Feinberg lab has built a first-of-its-kind microphysiologic system, or tissue model, entirely out of collagen. Share Traditionally, tiny models of human tissue that mimic human physiology, known as microfluidics, organ-on-chip, or microphysiologic systems, have been made using synthetic materials such as silicone rubber or plastics, because that was the only way researchers could build these devices. Because these materials aren't native to the body, they cannot fully recreate the normal biology, limiting their use and application. 'Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,' explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon. 'Most importantly, these models are fully biologic, which means cells function better.' In new research published in Science Advances, the group demonstrates use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter. 'It is paramount for everyone to understand the importance of team-based science in developing these technologies and the value varied expertise brings both to the project, and our impact on society,' elaborated Feinberg. This technology is currently being commercialized by FluidForm Bio, a Carnegie Mellon spinout company. Feinberg and his collaborators are committed to releasing open-source designs and other technologies that allow for broad adoption within the research community. 'We're hoping that very quickly, other labs in the world will adopt and expand this capability to other disease and tissue areas,' Feinberg added. 'We see this as a base platform for building more complex and vascularized tissue systems.'
